January 17, 2024

The Honorable Mike Braun
United States Senate
404 Russell Senate Office Building
Washington, D.C. 20510

The Honorable Gary Peters
United States Senate
724 Hart Senate Office Building
Washington, D.C. 20510

RE: Support for Dillon’s Law (S. 3575)

Dear Senators Braun and Peters:

I write on behalf of the American Academy of Allergy, Asthma & Immunology (AAAAI) to thank you for your introduction of S. 3575, Dillon’s Law. The AAAAI supports this legislation that would incentivize states, using existing grants, to expand epinephrine training programs.

Established in 1943, the AAAAI is a professional organization with more than 7,000 members in the United States, Canada and 72 other countries. This membership includes board certified allergist/immunologists, other medical specialists, allied health and related healthcare professionals – all with a special interest in the research and treatment of patients with allergic and immunological diseases.

Anaphylaxis can result from insect stings, food items, and medications with 500-1,000 fatalities annually and many more hospitalizations and emergency department visits. The Centers for Disease Control and Prevention (CDC) reports that the prevalence of food allergies in children increased by 50 percent between 1997 and 2011. Between 1997 and 2008, the prevalence of peanut or tree nut allergy appears to have more than tripled in U.S. children. About 40 percent of children with food allergies have experienced a severe reaction, such as anaphylaxis. Each year, more than 200,000 Americans require emergency medical care for allergic reactions to food: equivalent to one trip to the emergency room every three minutes.

S. 3575, named in memory of Dillon Mueller, will help to prevent tragedies among allergic individuals including anaphylaxis by creating a preference under an existing preventive health services federal grant program for states that allow trained individuals to carry and administer epinephrine to someone suffering from a severe allergic reaction.

(more)
On behalf of the patients we serve, thank you for your leadership in bringing attention to the issue of severe allergic reactions. The AAAAI looks forward to working with you to advance this important legislation. Please contact Sheila Heitzig, JD, MNM, CAE, AAAAI Director of Practice and Policy, at (414) 272-6071 or sheitzig@aaaai.org if you have any questions.

Sincerely,

Jonathan A. Bernstein, MD FAAAAI
President, American Academy of Allergy, Asthma & Immunology